tetano
Editor, Senior Moderator
Am J Transplant
. 2021 Jul 13.
doi: 10.1111/ajt.16764. Online ahead of print.
Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19
Ilies Benotmane[SUP] 1 2 [/SUP], Gabriela Gautier-Vargas[SUP] 1 [/SUP], Floriane Gallais[SUP] 2 3 [/SUP], Pierre Gantner[SUP] 2 3 [/SUP], Noelle Cognard[SUP] 1 [/SUP], Jerome Olagne[SUP] 1 [/SUP], Aurélie Velay[SUP] 2 3 [/SUP], Francoise Heibel[SUP] 1 [/SUP], Laura Braun-Parvez[SUP] 1 [/SUP], Jonas Martzloff[SUP] 1 [/SUP], Peggy Perrin[SUP] 1 [/SUP], Bruno Moulin[SUP] 1 2 [/SUP], Samira Fafi-Kremer[SUP] 2 3 [/SUP], Sophie Caillard[SUP] 1 2 [/SUP]
Affiliations
Abstract
A recent study demonstrated that a single dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological response in immunocompetent subjects with a previous history of coronavirus disease 2019 (COVID-19).[SUP]1,2[/SUP] While research has suggested that immunocompromised kidney transplant recipients (KTRs) who received mRNA-based vaccines show low immunization rates,[SUP]3-5[/SUP] the question as to whether this also applies to KTRs with a past history of COVID-19 remains unanswered. The aim of this study was to describe the results of immunization after one dose of the mRNA-1273 SARS-CoV-2 vaccine in KTRs who were already seropositive at baseline because of previous exposure to SARS-CoV-2.
. 2021 Jul 13.
doi: 10.1111/ajt.16764. Online ahead of print.
Strong antibody response after a first dose of a SARS-CoV-2 mRNA-based vaccine in kidney transplant recipients with a previous history of COVID-19
Ilies Benotmane[SUP] 1 2 [/SUP], Gabriela Gautier-Vargas[SUP] 1 [/SUP], Floriane Gallais[SUP] 2 3 [/SUP], Pierre Gantner[SUP] 2 3 [/SUP], Noelle Cognard[SUP] 1 [/SUP], Jerome Olagne[SUP] 1 [/SUP], Aurélie Velay[SUP] 2 3 [/SUP], Francoise Heibel[SUP] 1 [/SUP], Laura Braun-Parvez[SUP] 1 [/SUP], Jonas Martzloff[SUP] 1 [/SUP], Peggy Perrin[SUP] 1 [/SUP], Bruno Moulin[SUP] 1 2 [/SUP], Samira Fafi-Kremer[SUP] 2 3 [/SUP], Sophie Caillard[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34254431
- DOI: 10.1111/ajt.16764
Abstract
A recent study demonstrated that a single dose of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-based vaccine is sufficient to mount a robust immunological response in immunocompetent subjects with a previous history of coronavirus disease 2019 (COVID-19).[SUP]1,2[/SUP] While research has suggested that immunocompromised kidney transplant recipients (KTRs) who received mRNA-based vaccines show low immunization rates,[SUP]3-5[/SUP] the question as to whether this also applies to KTRs with a past history of COVID-19 remains unanswered. The aim of this study was to describe the results of immunization after one dose of the mRNA-1273 SARS-CoV-2 vaccine in KTRs who were already seropositive at baseline because of previous exposure to SARS-CoV-2.